We are live on ! Find out more
KCM

Kalehua Capital Management Portfolio holdings

AUM $174M
This Fund
S&P 500
This Quarter Est. Return
+26.81%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$101M
AUM Growth
–
Cap. Flow
+$97.9M
Cap. Flow %
96.83%
Top 10 Hldgs %
83.53%
Holding
19
New
19
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
BOXX icon
Alpha Architect 1-3 Month Box ETF
BOXX
+$26.4M
2
XFOR icon
X4 Pharmaceuticals
XFOR
+$13.5M
3
SION
Sionna Therapeutics
SION
+$7.47M
4
RLAY icon
Relay Therapeutics
RLAY
+$6.43M
5
SRZN icon
Surrozen
SRZN
+$6.23M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 73.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOXX icon
1
Alpha Architect 1-3 Month Box ETF
BOXX
$14B
$26.6M 26.27%
+230,787
New +$26.4M
XFOR icon
2
X4 Pharmaceuticals
XFOR
$402M
$14.9M 14.73%
+3,722,840
New +$13.5M
SION
3
Sionna Therapeutics
SION
$253M
$8.11M 8.02%
+197,072
New +$7.47M
RLAY icon
4
Relay Therapeutics
RLAY
$4.33B
$7.63M 7.54%
+901,457
New +$6.43M
CMPS
5
Compass Pathways
CMPS
$1.97B
$5.66M 5.59%
+819,692
New +$5M
PHVS icon
6
Pharvaris
PHVS
$2.62B
$5.52M 5.46%
+198,772
New +$4.79M
SEPN
7
Septerna Inc
SEPN
$1.89B
$5.42M 5.36%
+194,544
New +$4.65M
ORKA
8
Oruka Therapeutics
ORKA
$6.78B
$3.59M 3.55%
+118,524
New +$3.3M
IKT icon
9
Inhibikase Therapeutics
IKT
$349M
$3.59M 3.55%
+1,750,000
New +$2.78M
ALLO icon
10
Allogene Therapeutics
ALLO
$701M
$3.49M 3.45%
+2,546,129
New +$3.36M
LONA
11
LeonaBio Inc
LONA
$72.8M
$2.98M 2.95%
+393,701
New +$1.8M
MLTX icon
12
MoonLake Immunotherapeutics
MLTX
$1.31B
$2.32M 2.29%
+175,734
New +$2.07M
ORIC icon
13
Oric Pharmaceuticals
ORIC
$1.4B
$2.18M 2.16%
+267,059
New +$3.07M
VRCA icon
14
Verrica Pharmaceuticals
VRCA
$83.7M
$1.96M 1.94%
+235,779
New +$1.31M
TYRA icon
15
Tyra Biosciences
TYRA
$1.56B
$1.96M 1.94%
+74,465
New +$1.37M
SRZN icon
16
Surrozen
SRZN
$282M
$1.89M 1.87%
+385,178
New +$6.23M
TNYA icon
17
Tenaya Therapeutics
TNYA
$151M
$1.42M 1.41%
+2,000,000
New +$2.72M
KLRS
18
Kalaris Therapeutics
KLRS
$97.6M
$1.18M 1.17%
+139,901
New +$895K
DMAC icon
19
DiaMedica Therapeutics
DMAC
$352M
$759K 0.75%
+95,359
New +$713K

Similar funds

PWSG
Pacific Wealth Strategies Group Santa Barbara, California $174M AUM 21.47% 1-Year Est. Return
6SA
6th Street Advisors Daphne, Alabama $174M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $174M AUM
PIA
Prakash Investment Advisors Andover, Massachusetts $174M AUM 85.35% 1-Year Est. Return
CPCP
Cedar Point Capital Partners Cedar Rapids, Iowa $174M AUM 19.71% 1-Year Est. Return
PMSA
Patrick M. Sweeney & Associates Libertyville, Illinois $174M AUM 29.38% 1-Year Est. Return
MCM
MontVue Capital Management Lynchburg, Virginia $174M AUM 24.95% 1-Year Est. Return
AIA
Accelerate Investment Advisors Aliso Viejo, California $174M AUM 23.04% 1-Year Est. Return

Kalehua Capital Management's Q4 2025 Portfolio in Review

Q4 2025 is the first quarter with a 13F filing on record for Kalehua Capital Management, which disclosed 19 positions worth $101M. Its ten largest holdings account for 84% of the portfolio.

Its largest position is Alpha Architect 1-3 Month Box ETF: 230,787 shares worth $26.6M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets.

  • Kalehua Capital Management's largest Q4 2025 buy was Alpha Architect 1-3 Month Box ETF: 230,787 shares worth $26.6M.
  • Kalehua Capital Management's ten largest holdings make up 84% of its $101M portfolio in Q4 2025.
  • Kalehua Capital Management disclosed 19 positions in Q4 2025, its first 13F filing on record.

Based on Kalehua Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.